All these agents represent new research tools for the discovery and development of efficient BCRP inhibitors, which may have potential use, per se or in combination, for the treatment of cancer and for the design of rational analogues with higher activity, less toxicity and fewer pharmacokinetic interactions. The gene discussed is ABCG2; the disease is cancer.